Trial record 19 of 61 for:    "Asperger Syndrome"

Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism

This study has been withdrawn prior to enrollment.
(grant was not approved.)
Sponsor:
Information provided by:
Yellen & Associates, Inc.
ClinicalTrials.gov Identifier:
NCT00693953
First received: June 5, 2008
Last updated: October 1, 2009
Last verified: October 2009
  Purpose

Individuals with Autism Spectrum Disorder will have abnormal DESA® results. Our objective is to use neuroelectrical measures to determine the degree of processing abnormalities in individuals with Autism. The study will survey processing patterns and will locate and evaluate the degree(s) of abnormalities for further study. The abnormal results of comprehensive neuroelectrical evaluations of individuals with Autism when compared to the normative database will provide objective, verifiable, neurophysiological information with which to form novel approaches to the disorder.


Condition
Autistic Disorder
Autism, Early Infantile
Autism, Infantile
Asperger Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism

Resource links provided by NLM:


Further study details as provided by Yellen & Associates, Inc.:

Estimated Enrollment: 200
Study Start Date: January 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Year one
2
Year two

Detailed Description:

The research method will be: gathering, analyzing and utilizing data.

We will observe research subjects through neuroelectrical instrumentation, then, compare results to retrospective information collected from research subjects and a normative database.

A qualified neurologist thoroughly familiar with electrophysiology will interpret the data, and analyze it to explore the abnormalities.

The hypothesis will be evaluated.

We will, then, utilize the results to find data-based forms of treatment for those with the disorder.

  Eligibility

Ages Eligible for Study:   5 Years to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study population includes individuals with Autism without exclusion on the basis of sex, gender, race or ethnicity. There will be 100 research subjects, with a ratio of four males to one female, and those being approximately sixty-five children and thirty-five adults.

Criteria

Inclusion Criteria:

  • The study will include children between the ages of five and eighteen, adults from the age of nineteen to twenty-five, and those with the diagnosis of Autism and Autism Spectrum Disorders.

Exclusion Criteria:

  • those with mental retardation
  • those with any other neurological disorder
  • those that cannot sit in a chair for one hundred and fifty minutes
  • those that have been previously diagnosed with a seizure disorder
  • those who are blind and/or deaf
  • those who are not ambulatory
  • those who cannot understand English
  • those that are not a resident of Los Angeles County
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00693953

Locations
United States, California
Yellen & Associates, Inc.
Northridge, California, United States, 91326
Sponsors and Collaborators
Yellen & Associates, Inc.
Investigators
Principal Investigator: Andrew G Yellen, PhD President, Yellen & Associates, Inc.
Study Chair: Thomas Schweller, MD Neurologist
  More Information

No publications provided

Responsible Party: Dr. Andrew G. Yellen, Yellen & Associates, Inc.
ClinicalTrials.gov Identifier: NCT00693953     History of Changes
Other Study ID Numbers: PA-06-278
Study First Received: June 5, 2008
Last Updated: October 1, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Yellen & Associates, Inc.:
Evoked Potentials
Evoked Potentials, Auditory
Evoked Potentials, Visual
Electroencephalography
Brain Mapping

Additional relevant MeSH terms:
Congenital Abnormalities
Autistic Disorder
Asperger Syndrome
Child Development Disorders, Pervasive
Mental Disorders Diagnosed in Childhood
Mental Disorders

ClinicalTrials.gov processed this record on July 22, 2014